news

NIBRT announces collaboration to improve downstream bioprocessing bottlenecks

6
SHARES

A collaboration between the NIBRT and Avantor aims to address issues faced in downstream bioprocessing during buffer preparation for mAbs.

Antibody near cells

The National Institute of Bioprocessing Research and Training (NIBRT) in Ireland has announced its collaboration with Avantor to address downstream bioprocessing bottlenecks in buffer preparation when producing monoclonal antibodies (mAbs).

 

Reserve your FREE place

 


Address the time-to-result challenge posed by short shelf-life radiopharmaceuticals.

20 November 2025 | 3:00 PM GMT | FREE Virtual Panel Discussion

This webinar showcases the Growth Direct System; an RMM (Rapid Microbial Method) that improves on traditional membrane filtration, delivering increased accuracy, a faster time to result, enhanced data integrity compliance, and more control over the manufacturing process.

Key learning points:

  • Understand the benefits of full workflow microbiology quality control testing automation in radiopharmaceutical production
  • Learn about ITM’s implementation journey and considerations when evaluating the technology
  • Find out how the advanced optics and microcolony detection capabilities of Growth Direct® technology impact time to result (TTR).

Don’t miss your chance to learn from experts in the industry – Register for FREE

 

According to the NIBRT, the new in-line dilution systems from this partnership will complement the organisation’s bioprocessing capabilities.

Buffer management can help to advance bioprocessing production by reducing downstream bottlenecks and costs”

Dominic Carolan, NIBRT Chief Executive Officer, stated: “This collaboration further advances our mission of providing a world-class research and training centre of excellence. Technicians and professionals will benefit from access to the latest bioprocessing production knowledge, technology and innovation in buffer management.”

Buffers are a critical component when producing and purifying mAbs and are extensively used in upstream and downstream production. Recent activities in upstream optimisation have resulted in increasing production yields, which has now placed pressure on downstream purification resources. In addition, demand for multi-product facilities has placed a strain on capacity for traditional buffer preparation.

Dr Ger Brophy, Executive Vice President, Biopharma Production for Avantor, said: “Demand for therapeutic biologics is increasing and this will require increased manufacturing productivity. At the same time, there is significant pressure on the biopharma industry to reduce overall costs while ensuring that safety and quality are not compromised. This has resulted in initiatives to improve efficiency and increase flexibility in bioprocessing facilities. Buffer management is a key process step which is prime for optimisation.” 

Buffer management can help to advance bioprocessing production by reducing downstream bottlenecks and costs. The NIBRT says that this collaboration will provide industry-leading buffer management training to help mitigate downstream challenges, which will help new therapies to reach patients faster and more cost effectively.

“We’re proud to be collaborating with NIBRT to move science forward through innovation, training and hands-on experience with the latest technology,” added Dr Brophy. 

Share via
Share via